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Enhancer of zeste homologue 2 (EZH2), a member of the polycomb group protein family, plays a crucial role in the regulation of
embryonic development and has been associated with the regulation of the cell cycle. Recently, several studies have shown that
EZH2 is highly expressed in aggressive tumours, including human breast cancer, prostate cancer, and lymphomas. We thus analysed
EZH2 expression using real-time reverse transcription–polymerase chain reaction, and correlated its expression status with various
clinicopathological parameters in 66 patients with hepatocellular carcinoma (HCC). We found high expression of EZH2 in human
liver cancer cell lines. Furthermore, EZH2 gene-expression levels in tumour tissue specimens (0.3470.52) were significantly higher
(Po0.0001) than those in the corresponding nontumour tissue specimens (0.0770.09). The incidence of cancer cell invasion into
the portal vein was significantly higher (Po0.001) in the high EZH2 expression group (26 of the 33, 79%) than in the low expression
group (13 of the 33, 39%). However, there was no significant difference in the disease-free survival rate between the two groups. The
findings of this study indicate that EZH2 mRNA expression was upregulated in human HCC and may play an important role in
tumour progression, especially by facilitating portal vein invasion.
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Polycomb group (PcG) proteins are known to maintain the
silenced state of several developmentally regulated genes and to
control the transcriptional memory of a cell (Laible et al, 1997; van
der Vlag et al, 1999). Dysregulation of this gene-silencing
machinery may lead to cancer (Jacobs et al, 1999; Satijin and
Otte, 1999). Recently, enhancer of zeste homologue 2 (EZH2), a
member of the PcG protein family, has been linked to the
aggressiveness of human cancers, including lymphomas (Raa-
phorst et al, 2000; van Kemenade et al, 2001; Visser et al, 2001;
Dukers et al, 2004), breast cancer (Kleer et al, 2003; Raaphorst
et al, 2003) and prostate cancer (Sellers and Loda, 2002;
Varambally et al, 2002; Rhodes et al, 2003; Foster et al, 2004).
Kleer et al (2003) provided biological evidence that overexpression
of EZH2 promotes oncogenic transformation. In breast epithelial
cells, they observed that high expression of EZH2 induced
anchorage-independent growth and cell invasion, behaviours that
are hallmarks of cancer. Moreover, they found that higher
expression levels of EZH2 protein were strongly associated with
decreased disease-free survival and decreased overall survival for
patients with breast cancer. In addition, Varambally et al (2002)
reported that EZH2 was overexpressed in metastatic prostate
cancer and that inhibition of EZH2 blocked prostate cell growth.
EZH2 expression has also been demonstrated to have prognostic
significance in patients with prostate cancer (Sellers and Loda,
2002; Varambally et al, 2002; Rhodes et al, 2003; Foster et al, 2004).
Therefore, the role of EZH2 in tumour development and
progression has recently become a subject of increased interest
(Tonini et al, 2004). To the best of our knowledge, however, the
clinicopathological and prognostic significance of the EZH2 gene-
expression status has not previously been examined in digestive
organ cancers. The present study thus focused on examining the
relationship between EZH2 mRNA expression and clinicopatholo-
gical features of human hepatocellular carcinoma (HCC), using
real-time quantitative reverse transcription–polymerase chain
reaction (RT–PCR).
MATERIALS AND METHODS
Cell lines
The human liver cancer cell lines, Hep3B, HepG2 and HuH7, were
provided by the Cell Resource Center for Biomedical Research,
Institute of Development, Aging and Cancer, Tohoku University,
Japan. All cell lines were maintained in an RPMI 1640 medium
supplemented with 10% foetal calf serum and antibiotics. Cultured
cells from each cell line were dissolved in 350ml of buffer RLT
containing 1% beta-mercaptoethanol and total RNA was extracted
and purified by RNeasy Mini Kit (Qiagen, Hilden, Germany) in
accordance with the manufacturer’s protocols.
Received 5 October 2004; revised 17 February 2005; accepted 28
February 2005; published online 26 April 2005
*Correspondence: Dr M Mori; E-mail: mmori@beppu.kyushu-u.ac.jp
British Journal of Cancer (2005) 92, 1754–1758
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sClinical tissue samples
In all, 66 patients with HCC who underwent surgery at our
institutes were entered in this study. The resected tumour and
paired nontumour tissue specimens were immediately frozen in
liquid nitrogen and kept at  801C until analysis. Frozen tissue
specimens were homogenised in guanidinium thiocyanate, and
total RNAs were obtained by ultracentrifugation through a cesium
chloride cushion as described previously (Mori et al, 1995;
Utsunomiya et al, 2002a). Written informed consent was obtained
from all patients. All patients were closely followed after surgery at
regular 1-month intervals.
Real-time quantitative RT–PCR
Sense and antisense primers encoding the middle portion of the
EZH2 gene located on chromosome 7q35, including intron and
exon sequences, were designed and constructed. The sequences of
the EZH2 primers were as follows: sense primer, 50-TTGTTGGCGG
AAGCGTGTAAAATC-30; and antisense primer, 50-TCCCTAGTCC
CGCGCAATGAGC-30. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as an internal control. The sequences of the
GAPDH primers were as follows: sense, 50-TGAACGGGAAGCTCA
CTGG-30; and antisense, 50-TCCACCACCCTGTTGCTGTA-30. Real-
time monitoring of the PCR reactions was performed using the
LightCyclerTM system (Roche Applied Science, Indianapolis, IN,
USA) and SYBR green I dye (Roche Diagnostics). Monitoring was
performed according to the manufacturer’s instructions, as
described previously (Utsunomiya et al, 2002b; Ogawa et al,
2004). In brief, a master mixture was prepared on ice containing
1ml of cDNA of each gene, 2ml of LC DNA Master SYBR Green I
mix, 50ng of primers and 2.4mlo f2 5m M MgCl2. The final volume
was then adjusted to 20ml with water. After the reaction mixture
was loaded into the glass capillary tube, PCR was carried out under
the following cycling conditions: initial denaturation at 951C for
10min, followed by 35 cycles of denaturation at 951C for 1min,
annealing at 561C for 1min and extension at 721C for 1min. After
amplification, the products were subjected to a temperature
gradient from 68 to 951C at 0.21Cs
 1 under continuous fluore-
scence monitoring to produce a melting curve of the products. We
determined the expression levels of EZH2 and GAPDH by
comparison with Hep3B cDNA. The fit point method was
employed to determine the cycle in which the log-linear signal
was first distinguishable from the baseline, and that cycle number
was then used as a crossing-point value. The standard curve
was produced by measuring the crossing point of each standard
value and plotting them against the logarithmic value of
concentration. The EZH2 concentration of each sample was
calculated by plotting their crossing points against the standard
curve. EZH2 concentration was then divided by the concentration
of endogenous reference (GAPDH) to obtain normalised
EZH2 expression. Each assay was performed three times to verify
the results, and the mean mRNA expression was used for the
statistical analysis.
Immunohistochemical analysis
Several formalin-fixed and paraffin-embedded tissue sections
corresponding to the samples used for mRNA expression analysis
were analysed. Tissue sections were deparaffinised, soaked in
0.01 M sodium cytorate buffer and boiled in an electronic oven for
15min at 500W to retrieve cell antigens. The tissue sections were
immunohistochemically stained using the streptavidin–biotin
peroxidase method (Universal Dako Cytomation LSAB
s kit; Dako,
Kyoto, Japan) with a primary antibody against EZH2 (rabbit
polyclonal antibody; ABGENT, San Diego, USA). In brief, the
sections were blocked by 3% H2O2 for 5min and incubated
overnight with primary antibody at 41C. The samples were then
washed with TBS buffer and subsequently incubated with
secondary antibody for 30min.
Statistical analysis
The data obtained from real-time RT–PCR and the patients’
clinicopathological variables were processed by the statistical
software JMP (SAS Institute Inc., Cary, NC, USA). The Student’s
t-test and the w
2 test with Yates’ correction factor were used.
The postoperative disease-free survival rate was calculated by
the Kaplan–Meier method, and the differences in survival
between the groups were compared using the log-rank test. The
findings were considered to be significant when their P-value was
less than 0.05.
RESULTS
Expression of EZH2 in cell lines and clinical samples
We first examined EZH2 mRNA expression in three human
liver cancer cell lines and found sufficient EZH2 expression in
all the cell lines (Figure 1). We then determined the levels of
EZH2 mRNA expression by comparisons with Hep3B as the
EZH2
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Figure 1 Expression of EZH2 in three liver cancer cell lines (Hep3B,
HepG2 and HuH7). M: marker; P: positive control (Human Universal
Reference total RNA, Clontech, Palo Alto, CA, USA); N: negative control
(distilled water); GAPDH: glyceraldehyde-3-phosphate dehydrogenase.
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Figure 2 Expression levels of EZH2 quantitatively determined by real-
time RT–PCR for 66 pairs of tumour and nontumour tissue specimens.
The correction values of EZH2 expression were calculated by dividing the
EZH2 amounts by the amount of endogenous reference (GAPDH)
concurrently examined on the same samples.
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The mean expression level of EZH2 mRNA in tumour tissue
specimens, 0.3470.52, was significantly higher than the mean
expression level, 0.0770.09, of EZH2 in the corresponding
nontumour tissue specimens (Po0.0001), as shown in Figure 2.
Patients with mRNA expression levels in tumour tissue less
than the median value of 0.14 formed the low expression
group (n¼33), while patients with mRNA expression levels in
tumour tissue equal to or greater than 0.14 formed the high
expression group (n¼33).
Immunohistochemical staining
To visualise the localisation of EZH2 protein, immunohistochem-
ical studies were performed in the resected HCC tissue specimens.
Representative findings are shown in Figure 3. EZH2 staining was
markedly stronger in the cytoplasm of HCC cells than in the
cytoplasm of noncancerous hepatocytes. These findings corre-
sponded well with the results of real-time RT–PCR analysis.
EZH2 mRNA expression and clinicopathological
characteristics
Clinicopathological factors analysed according to the General
Rules for Clinical and Pathological Study of Primary Liver Cancer
(Liver cancer study group of Japan, 2000) are shown in Table 1 in
relation to EZH2 mRNA expression in tumour tissue. No
significant differences in host factors, such as the patient’s age,
sex and the results of liver function tests, were observed between
the high and low expression groups. On the other hand, the
incidence of cancer cell invasion to the portal vein was
significantly higher (Po0.001) in the high expression group (26
of the 33, 79%) than in the low expression group (13 of the 33,
39%). Other pathological variables, such as the tumour diameter,
capsular formation and intrahepatic metastasis, did not signifi-
cantly correlate with the EZH2 expression status in tumour tissue
specimens. Comparison of the disease-free survival rates of the low
expression (n¼33) and high expression (n¼33) groups, shown in
Figure 4, revealed no significant difference in the disease-free
survival rate between the two groups.
DISCUSSION
Recent studies have shown that EZH2 is highly expressed in several
advanced cancers (Raaphorst et al, 2000; van Kemenade et al, 2001;
NT
Figure 3 An immunohistochemical analysis for EZH2 in HCC. EZH2
immunostaining was strongly positive in the cytoplasm of the HCC cells,
whereas it was weakly positive in the corresponding normal liver cells. N:
nontumour tissue; T: tumour tissue.
Table 1 Clinicopathological data and EZH2 mRNA expression in the tumour tissue specimens from 66 patients with HCC
Variables Low expression group
a (n¼33) High expression group
a (n¼33) P-value
Sex (male:female) 21:12 21:12 0.99
Age (years) 64.679.3 62.1710.4 0.31
Liver function
HbsAg (+) (%) 2.3 (4/33) 30.3 (10/33) 0.07
HCV antibody (+) (%) 63.6 (21/33) 69.7 (23/33) 0.60
Platelet count  10
4 (ml
 1) 95.5715.9 75712.2 0.31
Prothrombin time (%) 91.973.5 87714.3 0.28
Albumin (gdl
 1) 3.870.1 3.970.1 0.38
Total bilirubin (mgdl
 1) 0.970.1 0.970.1 0.85
ALT (IUl
 1)5 3 77.1 55.676 0.79
ICGR15 (%) 17.371.8 14.671.7 0.27
Tumour factors
Tumour size (cm) 3.970.3 5.170.6 0.07
fc (+) (%) 84.8 (28/33) 78.8 (26/33) 0.52
fc-inf (+) (%) 65.6 (21/32) 71.9 (23/32) 0.59
vp (+)(%) 39.3 (13/33) 78.8 (26/33) o 0.001
vv (+)(%) 6.1 (2/33) 9.1 (3/33) 0.59
b(+) (%) 3.0 (1/33) 12.1 (4/33) 0.15
im (+)(%) 36.4 (12/33) 42.4 (14/33) 0.61
Well/moderately/poorly
b 5/22/6 1/21/11 0.12
Staging
I (%) 18.2 (6/33) 0.1 (1/32) 0.22
II (%) 27.3 (9/33) 37.5 (12/32)
III (%) 30.0 (10/33) 33.3 (11/32)
IV (%) 0.1 (8/33) 25 (8/32)
HCC¼hepatocellular carcinoma; HBsAg¼hepatitis B surface antigen; HCV¼hepatitis C virus; AST¼aspartate transaminase; ICG R15¼indocyanine green dye retention test
at 15min; fc¼capsular formation; fc-inf¼tumour invasion to fc; vp¼invasion to portal vein; vv¼invasion to hepatic vein; b¼invasion to bile duct; im¼intrahepatic metastasis.
aThe low and high expression groups were determined by a median value of EZH2 mRNA in the 66 tumour tissue specimens.
bHistologic differentiation of the tumour.
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Kleer et al,2 0 0 3 ;R h o d e set al, 2003; Raaphorst et al, 2003; Dukers
et al, 2004; Foster et al, 2004). The question naturally arises whether
EZH2 actually contributes to tumour development or whether it is
just a biomarker of tumour progression. Bracken et al (2003)
provided evidence for EZH2 being an actual contributor to tumour
development by demonstrating that EZH2 is located downstream in
the retinoblastoma protein (pRB) pathway and is an essential
downstream mediator of E2F function, which is required for cell
proliferation. Bracken et al also demonstrated a direct link between
the pRB-E2F growth control pathway and chromatin modifications
and identified EZH2 as a strong candidate oncogene. Tonini et al
showed that EZH2 reverses pRb2/p130-histone deacetylase-mediated
repression of the cyclin A promoter, suggesting a molecular
mechanism linking increased EZH2 expression with malignant
transformation (Tonini et al, 2004).
Although an association between the tumour aggressiveness and
the overexpression of EZH2 has been well documented for breast
cancer (Kleer et al, 2003; Raaphorst et al, 2003) and prostate
cancer (Sellers and Loda, 2002; Varambally et al, 2002; Rhodes
et al, 2003; Foster et al, 2004), little is known about the expression
status of EZH2 in digestive organ cancers. In the present study, we
found that EZH2 mRNA was highly expressed in human liver
cancer cell lines as well as in primary tumours from HCC patients.
We then examined the clinicopathological features of EZH2
expression in HCC patients. Interestingly, we observed a
statistically significant difference in the incidence of portal vein
invasion between the high expression group (79%) and the low
expression group (39%). Molecular mechanisms linking high
EZH2 expression with an increased incidence of HCC portal vein
invasion are not known at present. However, Varambally et al
(2002) provided evidence that metastatic PC3 prostate cancer cells
treated with EZH2 small interference RNA showed a marked
inhibition of cell growth and proliferation. Kleer et al reported that
cells forming intravascular tumour emboli had markedly increased
EZH2 expression, suggesting that EZH2 may play an important
role in vascular invasion and breast cancer metastasis. Further-
more, Kleer et al (2003) confirmed the invasive properties of
EZH2-overexpressing cells both in an in vitro assay, using a
basement membrane invasion chamber, as well as in an in vivo
assay, using a chicken chorioallantoic membrane.
Since the presence of portal vein invasion is one of the most
important prognostic factors for HCC patients (Izumi et al, 1994;
Shimada et al, 1998; Ikai et al, 2004), we therefore investigated a
possible correlation between EZH2 mRNA values, quantitatively
determined by a real-time RT–PCR, and the prognosis of HCC
patients. In the present study, however, we found no significant
difference in the disease-free survival rate between the high
expression group and the low expression group. This finding
appears to be inconsistent with previous studies reporting on the
prognostic implications of increased EZH2 expression in patients
with breast cancer (Kleer et al, 2003; Raaphorst et al, 2003) and
prostate cancer (Sellers and Loda, 2002; Varambally et al, 2002;
Rhodes et al, 2003; Foster et al, 2004). Differences in tumour
aggressiveness between HCC and breast or prostate cancer may
explain such discrepant results, because the prognosis of patients
with HCC (30% 4-year disease-free survival rate in this study) is
markedly worse in general than the prognosis of patients with
breast or prostate cancer. Alternatively, these results may suggest
that EZH2 expression status is strongly associated with prognosis
only in patients with malignancies from hormonally regulated
tissues such as breast and prostate (Kleer et al, 2003).
In conclusion, the present study demonstrated that the
expression of EZH2 mRNA was upregulated in primary HCC
tissues and was associated with a significantly increased incidence
of portal vein invasion. Therefore, the EZH2 expression status may
be a significant indicator for identifying the malignant potential of
human HCC. However, the precise function of EZH2 in digestive
organ cancers such as HCC remains unclear. Further investigation
is therefore needed to clarify the relationship between EZH2 and
disease progression in cancer patients.
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